Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
2003

Combining Temozolomide and Procarbazine for Gliomas

Sample size: 28 publication Evidence: moderate

Author Information

Author(s): Newlands E S, Foster T, Zaknoen S

Primary Institution: Imperial College School of Medicine

Hypothesis

Does combining procarbazine with temozolomide increase the therapeutic index in treating malignant gliomas?

Conclusion

The combination of temozolomide and procarbazine is a reasonably effective and well-tolerated treatment for patients with relapsed gliomas.

Supporting Evidence

  • The overall response rate to the combination treatment was 36%.
  • Responses were seen in all types of glioma.
  • The combination was well tolerated at doses up to level 3.

Takeaway

This study tested a new medicine combination to help people with brain tumors, and it seems to work pretty well without causing too many problems.

Methodology

28 patients with malignant gliomas were treated with temozolomide and escalating doses of procarbazine, assessing responses clinically and radiologically.

Limitations

The study was limited by a small sample size and the interruption of procarbazine supply.

Participant Demographics

{"gender":{"male":17,"female":11},"age":{"median":47,"range":"18–67"}}

Digital Object Identifier (DOI)

10.1038/sj.bjc.6601043

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication